In MCF-7 breast cancer cells EGCG inhibited the phosphorylation of ErbB2 and ErbB3 and suppressed the MAPK pathway [55,57], while in mammary tumor NF639 and SMF cells EGCG reportedly decreased cell proliferation, phosphorylation of ErbB2/neu and inhibited the NF-κB and MAPK pathways [55,58]. Here, ERBB2 is linked to breast cancer.